Alto Neuroscience | search
Click here to view Alto Neuroscience news from 60+ newspapers.
Bookmark or Share- Jan 10, 2023 Press Release - Alto NeuroscienceLOS ALTOS, Calif., January 10, 2023 – Alto Neuroscience Inc. today reported results from its Phase 2a study of ALTO-100, demonstrating clear evidence of efficacy and favorable safety in patients with MDD.
- Platform - Alto NeuroscienceOur Biomarker Platform. Built on more than 10 years of methods and data, using our AI-enabled platform we aim to better identify which patients are more likely to respond to our novel product candidates and drive drug development using biomarkers. We identify biomarkers similarly to how we built our pipeline – with a tight focus on core ...
- Alto Neuroscience, Inc. - Alto Neuroscience Announces Positive Phase 1 ...Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. Alto’s Precision Psychiatry Platform™ measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other ...
- Alto NeuroscienceWe are redefining psychiatry with AI-driven brain biomarkers that align the right patient with the right Alto drug, leveraging the richest in-human data set specifically built for precision psychiatry. Our work builds on a decade of clinical neuroscience research. Learn more. Leading Clinical-Stage Pipeline.
- Alto Neuroscience Announces Positive Results from Phase 2 Study of ALTO ...Alto Neuroscience is pioneering precision psychiatry by developing targeted medicines designed to help patients get better faster. Alto’s Precision Psychiatry Platform™ measures brain biomarkers by analyzing EEG activity, neurocognitive task performance, wearable data, and other factors to match each patient with the right Alto product ...
More
